Wells Fargo Cuts Target as Analysts Converge on TDG Caution

The bull and bear cases on the Street have not shifted materially. Bulls point to high-single to mid-teens organic growth in the commercial OE segment and 160 basis points of year-on-year margin expansion to 54.2%. Bears counter that FY2026 EBITDA guidance has been trimmed to $5.15 billion, below expectations, with EBITDA margin forecast to decline 140 basis points year-on-year as the Simmonds acquisition drags on the mix. UBS remains the most constructive name on the register, having raised its target to $1,695 after the August earnings print, but that note is now almost two months old. The PE multiple has compressed over the past month, down roughly 1.8 turns to 23.6x, while EV/EBITDA has slipped to 14.8x. Factor scores are unremarkable: short score ranks in the 59th percentile, EPS momentum at 90 days ranks 60th, and the analyst recommendation differential scores just 4 out of 100, reflecting the weight of cautious-to-neutral calls.

Short interest, meanwhile, has been building with enough pace to warrant attention even at a modest absolute level. Shorts have risen about 34% over the past month and 16% over the past week, with short interest now at roughly 2% of free float. That is not a crowded short by any standard, but the rate of change is meaningful. Borrowing remains cheap at 0.63% cost to borrow, up about 7.5% over the week. Availability is extremely loose at over 7,100%, meaning there is no constraint whatsoever on new short positions being established. The borrow market tells a story of incremental, low-friction short-building rather than a squeeze setup or an aggressive crowded short.

Options positioning has moderated from the extreme call-heavy tilt that characterised the prior week's note. The put/call ratio climbed back to 0.73 on September 29, up from a 52-week low of 0.49 set in the prior period. The 20-day average PCR is 0.88, and the current reading sits about 0.66 standard deviations below that mean, meaning options traders are still leaning toward calls but with less conviction than a week ago. The previous note flagged a PCR of 0.60 as the most bullish options setup in a year. That momentum has faded somewhat. The PCR history shows a clear regime shift: through August the ratio consistently ran above 1.0, heavy put demand, before collapsing sharply into mid-September as call buyers dominated. The current 0.73 reading sits in between, neither a defensive hedge nor the kind of aggressive bullish positioning seen two weeks ago.

On the ownership side, the recent insider activity deserves a note of caution about its interpretation. Eight directors received stock grants on September 18 at $1,085, totalling roughly $412,000 in aggregate. These are transaction code "A" awards, compensation grants rather than open-market purchases, and carry no informational signal about insider conviction on the stock's direction. The 90-day net insider position is negative, with net sales of around $18.4 million over the period. The activist register carries no 13D filer. The Vanguard Group filed a 13G/A in March disclosing a drop to 0% from 11.91%, a material exit by the index giant, with Vanguard Capital Management filing separately at 7.48% in April. Capital Research entities collectively hold well over 20% of shares, making them the dominant institutional voice in any governance conversation.

With the next earnings event scheduled for November 10, the question for the intervening six weeks is whether the current wave of target cuts stabilises or continues to pull the consensus anchor lower, and whether the short-building of the past month accelerates or plateaus as the print approaches.